Loading...
•
Jan 31
Engene Q1 2026 Earnings Report
Net loss widened as operating expenses increased to support clinical development of detalimogene.
Key Takeaways
enGene reported a higher net loss in Q1 2026 as operating expenses increased to support the LEGEND clinical trial and preparation for a planned BLA submission for detalimogene. The company maintains a strong balance sheet with over $312 million in cash and marketable securities expected to fund operations into the second half of 2028.
Net loss increased to 29752000 from 24616000 in the prior year quarter.
Total operating expenses rose to 31185000 driven by higher R&D and administrative costs.
Research and development expenses increased to 22255000 as clinical development activities expanded.
Cash, cash equivalents and marketable securities totaled 312549000 supporting runway into 2H 2028.
Forward Guidance
enGene plans to advance its lead program detalimogene through the LEGEND pivotal cohort with a planned BLA submission in the second half of 2026 and expects its current cash resources to fund operations into the second half of 2028.
Positive Outlook
- Planned BLA submission for detalimogene in the second half of 2026.
- LEGEND pivotal cohort update expected at a spring 2026 medical conference.
- 12-month complete response data expected in the second half of 2026.
- Cash runway projected into the second half of 2028.
- Expanded $125000000 debt facility provides additional financial flexibility.
Challenges Ahead
- Operating expenses increased year-over-year.
- Company continues to generate significant quarterly losses.
- Clinical development timelines carry regulatory risk.
- Future commercialization depends on successful BLA approval.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...